NextCure, Inc. (NXTC)
| Market Cap | 33.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.84M |
| Shares Out | 3.56M |
| EPS (ttm) | -19.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,243 |
| Open | 9.64 |
| Previous Close | 9.62 |
| Day's Range | 9.41 - 9.64 |
| 52-Week Range | 4.09 - 15.74 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+142.23%) |
| Earnings Date | May 4, 2026 |
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as w... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NXTC stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 142.23% from the latest price.
News
NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure Provides Business Update
BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided upd...
NextCure Transcript: Piper Sandler 37th Annual Healthcare Conference
Lead ADC programs SIM0505 and LNCB74 are progressing in phase I, with data expected in the first half of next year. The company is well-funded into 2027, plans further financing for phase II, and is spinning out non-oncology assets to maintain ADC focus.
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c...
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced th...
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced th...
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
BELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and S...
NextCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Two ADCs targeting gynecological and other tumors are in phase one, with unique constructs and patient selection strategies aiming for superior efficacy and safety. Key proof-of-concept data for both assets are expected in the first half of next year, supported by strong partnerships and financial resources.
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-...
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
BELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-...
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c...
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug
Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
BELTSVILLE, Md. and SHANGHAI, June 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class ...
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-cl...
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the f...
NextCure Transcript: 24th Annual Needham Virtual Healthcare Conference
LNCB74, a B7H4-targeted ADC, is in phase I for women's cancers, leveraging a stable glucuronidase linker for improved safety and efficacy. Clinical proof of concept is expected in early 2026, with a strong financial runway and active partnering for additional pipeline assets.
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-...
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-...
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed fo...
NextCure Transcript: Piper Sandler 36th Annual Healthcare Conference
IND filed for LNCB74, a novel ADC targeting B7-H4 in women's cancers, with phase 1 trials set to begin. Strategic partnerships are advancing other assets, including NC410, NC605, and NC181, while a $75M cash position funds operations into 2026.